MACK

Merrimack Pharmaceuticals, Inc. Press Releases

$11.78
*  
0.06
0.51%
Get MACK Alerts
*Delayed - data as of Mar. 4, 2015  -  Find a broker to begin trading MACK now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
2/26/2015 7:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer
2/19/2015 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
2/12/2015 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
1/22/2015 5:00:00 PM - GlobeNewswire


PharmaEngine Announces Phase 2 PEPCOL Study Presented at the 2015 ASCO GI of PEP02 (MM-398) in Combination with 5-FU/LV in Unresectable Metastatic Colorectal Cancer
1/21/2015 1:41:00 AM - Business Wire
▲15.26 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
1/20/2015 8:00:00 AM - GlobeNewswire


PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study Presented at the 2015 ASCO GI Substantiate the Positive Results of MM-398 in Combination with 5-FU/LV
1/19/2015 4:00:00 AM - Business Wire
▲17.80 % Price Change since this news event. The Volume Ratio is 1.52.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium
1/8/2015 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/7/2015 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
12/17/2014 8:00:00 AM - GlobeNewswire


Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
12/12/2014 8:00:00 AM - GlobeNewswire